Remy Luthringer Sells 2,194 Shares of Minerva Neurosciences, Inc (NERV) Stock

Minerva Neurosciences, Inc (NASDAQ:NERV) CEO Remy Luthringer sold 2,194 shares of Minerva Neurosciences stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.85, for a total transaction of $12,834.90. Following the transaction, the chief executive officer now owns 18,750 shares in the company, valued at approximately $109,687.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Minerva Neurosciences, Inc (NASDAQ NERV) traded up $0.20 during midday trading on Friday, reaching $5.95. 600,375 shares of the company were exchanged, compared to its average volume of 208,735. Minerva Neurosciences, Inc has a fifty-two week low of $4.80 and a fifty-two week high of $13.95.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter. During the same period last year, the company earned ($0.24) EPS. analysts expect that Minerva Neurosciences, Inc will post -1.28 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its stake in Minerva Neurosciences by 25.2% during the third quarter. Sterling Capital Management LLC now owns 52,135 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 10,479 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Minerva Neurosciences by 64.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 57,000 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 22,400 shares during the last quarter. Trexquant Investment LP bought a new position in Minerva Neurosciences during the third quarter worth $189,000. JPMorgan Chase & Co. bought a new position in Minerva Neurosciences during the third quarter worth $2,835,000. Finally, Sphera Funds Management LTD. raised its stake in Minerva Neurosciences by 31.9% during the third quarter. Sphera Funds Management LTD. now owns 625,000 shares of the biopharmaceutical company’s stock worth $4,750,000 after buying an additional 151,231 shares during the last quarter. 73.76% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Citigroup assumed coverage on shares of Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Minerva Neurosciences currently has a consensus rating of “Hold” and a consensus price target of $13.94.

WARNING: “Remy Luthringer Sells 2,194 Shares of Minerva Neurosciences, Inc (NERV) Stock” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://sportsperspectives.com/2017/12/17/remy-luthringer-sells-2194-shares-of-minerva-neurosciences-inc-nerv-stock.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply